keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer bone metastases

keyword
https://www.readbyqxmd.com/read/28072622/170tm-edtmp-a-prospective-alternative-of-89srcl2-for-theranostic-treatment-of-metastatic-bone-pain
#1
Tapas Das, Ajit Shinto, Koramadai Karuppuswamy Kamaleshwaran, Sharmila Banerjee
We have earlier reported the potential of Tm-EDTMP as an alternative cost-effective radiopharmaceutical of SrCl2 for bone pain palliation application. Encouraging results obtained in the radiochemical studies and biological evaluations in animal model have prompted us to initiate the clinical study to evaluate the potential of Tm-EDTMP in human cancer patients. The serial scintigraphic images represent the whole-body scans of a patient (68 years old woman) with skeletal metastases of carcinoma of the breast origin recorded after administering 370 MBq (10 mCi) of Tm-EDTMP at different post-administration time points along with the pre-therapy images recorded with Tc-MDP in the same patient...
January 9, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28069877/bone-seeking-matrix-metalloproteinase-2-inhibitors-prevent-bone-metastatic-breast-cancer-growth
#2
Marilena Tauro, Gemma Shay, Samer S Sansil, Antonio Laghezza, Paolo Tortorella, Anthony M Neuger, Hatem Soliman, Conor C Lynch
Bone metastasis is common during breast cancer progression. Matrix metalloproteinase-2 (MMP-2) is significantly associated with aggressive breast cancer and poorer overall survival. In bone, tumor or host derived MMP-2 contributes to breast cancer growth and does so by processing substrates including type I collagen and transforming growth factorβ (TGFβ) latency proteins. These data provide strong rationale for the application of MMP-2 inhibitors to treat the disease. However, in vivo, MMP-2 is systemically expressed...
January 9, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28069070/successful-management-of-synchronous-recurrent-breast-carcinoma-with-chronic-myelogenous-leukemia-a-case-report
#3
Choukri Elm'hadi, Mohamed Reda Khmamouche, Rachid Tanz, Mehdi Toreis, ElMehdi Mahtat, Mohammed Allaoui, Mohammed Oukabli, Nezha Messaoudi, Hassan Errihani, Mohammed Ichou
BACKGROUND: Survival is increasing after early breast cancer revealing frequent relapses and possibility of developing secondary malignancies. The concomitant occurrence of these two events is exceptionally disastrous and lethal. We report a case of a Moroccan woman who was successfully managed for synchronous recurrent breast carcinoma and chronic myelogenous leukemia. CASE PRESENTATION: A 42-year-old Moroccan woman was diagnosed with localized breast carcinoma in 2008...
January 10, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28058659/three-minute-spect-ct-is-sufficient-for-the-assessment-of-bone-metastasis-as-add-on-to-planar-bone-scintigraphy-prospective-head-to-head-comparison-to-11-min-spect-ct
#4
Helle D Zacho, José A Biurrun Manresa, Ramune Aleksyniene, June A Ejlersen, Joan Fledelius, Henrik Bertelsen, Lars J Petersen
BACKGROUND: The aim of this study is to assess whether ultra-fast acquisition SPECT/CT (UF-SPECT/CT) can replace standard SPECT/CT (std-SPECT/CT) as "add-on" to whole-body bone scintigraphy (WB-BS) for the investigation of bone metastases. Consecutive cancer patients referred for WB-BS who underwent SPECT/CT in addition to WB-BS were included. Std-SPECT, UF-SPECT, and low-dose CT were performed (std-SPECT: matrix 128 × 128, zoom factor 1, 20 s/view, 32 views; UF-SPECT: identical parameters except for 10 s/view and 16 views, reducing the acquisition time from 11 to 3 min)...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28049253/prostate-cancer-in-a-patient-with-a-family-history-of-brca-mutation-a-case-report-and-literature-review
#5
Won Hoon Song, Sung Han Kim, Jae Young Joung, Weon Seo Park, Ho Kyung Seo, Jinsoo Chung, Kang Hyun Lee
One of the most significant risk factors for prostate cancer (PC) is a family history of the disease, with germ-line mutations in the breast cancer predisposition gene (BRCA) 2 conferring the highest risk. We here report a 56-year-old man presented with painful gait disturbance and diagnosed PC with multiple disseminated bone metastases. The patient had a strong family history of breast cancer with his 2 nieces affected. Furthermore, his aunts and uncles from both sides were diagnosed with stomach, ovarian, and colorectal cancers...
February 2017: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/28048429/we-h-207a-07-image-based-versus-atlas-based-internal-dosimetry
#6
M Fallahpoor, M Abbasi, A Parach, F Kalantari
PURPOSE: Monte Carlo (MC) simulation is known as the gold standard method for internal dosimetry. It requires radionuclide distribution from PET or SPECT and body structure from CT for accurate dose calculation. The manual or semi-automatic segmentation of organs from CT images is a major obstacle. The aim of this study is to compare the dosimetry results based on patient's own CT and a digital humanoid phantom as an atlas with pre-specified organs. METHODS: SPECT-CT images of a 50 year old woman who underwent bone pain palliation with Samarium-153 EDTMP for osseous metastases from breast cancer were used...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28039445/aromatase-inhibitor-induced-bone-loss-increases-the-progression-of-estrogen-receptor-negative-breast-cancer-in-bone-and-exacerbates-muscle-weakness-in-vivo
#7
Laura E Wright, Ahmed A Harhash, Wende M Kozlow, David L Waning, Jenna N Regan, Yun She, Sutha K John, Sreemala Murthy, Maryla Niewolna, Andrew R Marks, Khalid S Mohammad, Theresa A Guise
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypothesized that AI-induced bone loss could increase breast cancer progression in bone and exacerbate muscle weakness associated with bone metastases. Female athymic nude mice underwent ovariectomy (OVX) or sham surgery and were treated with vehicle or AI (letrozole; Let)...
December 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/28030943/is-there-a-rationale-for-aggressive-breast-cancer-liver-metastases-resections-in-polish-female-patients-analysis-of-overall-survival-following-hepatic-resection-at-a-single-centre-in-poland
#8
Eliza Kobryń, Konrad Kobryń, Tadeusz Wróblewski, Krzysztof Kobryń, Radosław Pietrzak, Paweł Rykowski, Bogna Ziarkiewicz-Wróblewska, Krzysztof Lamparski, Krzysztof Zieniewicz, Waldemar Patkowski, Marek Krawczyk, Rafał Paluszkiewicz
INTRODUCTION: Breast cancer (BC) makes up nearly 26% of malignant tumours worldwide and is the leading cause of cancer-related deaths in European women. With approximately 18,000 new cases of BC diagnosed in Polish women annually, breast cancer liver metastasis (BCLM) is respectively an increasing issue. Recent data found in literature indicates improved survival following liver resection with systemic therapy. OBJECTIVE: The aim of study was to evaluate surgical treatment in patients with isolated BCLM...
23, 2016: Annals of Agricultural and Environmental Medicine: AAEM
https://www.readbyqxmd.com/read/28030702/effect-of-longer-interval-vs-standard-dosing-of-zoledronic-acid-on-skeletal-events-in-patients-with-bone-metastases-a-randomized-clinical-trial
#9
Andrew L Himelstein, Jared C Foster, James L Khatcheressian, John D Roberts, Drew K Seisler, Paul J Novotny, Rui Qin, Ronald S Go, Stephen S Grubbs, Tracey O'Connor, Mario R Velasco, Douglas Weckstein, Ann O'Mara, Charles L Loprinzi, Charles L Shapiro
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain. Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks. Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United States...
3, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28027521/correlation-between-severe-infection-and-breast-cancer-metastases-in-the-eortc-10994-big-1-00-trial-investigating-innate-immunity-as-a-tumour-suppressor-in%C3%A2-breast-cancer
#10
Nathan Touati, Konstantinos Tryfonidis, Franco Caramia, Hervé Bonnefoi, David Cameron, Leen Slaets, Belinda S Parker, Sherene Loi
BACKGROUND: Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti-tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo-adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones...
December 24, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/28027327/mutational-profile-of-metastatic-breast-cancers-a-retrospective-analysis
#11
Celine Lefebvre, Thomas Bachelot, Thomas Filleron, Marion Pedrero, Mario Campone, Jean-Charles Soria, Christophe Massard, Christelle Lévy, Monica Arnedos, Magali Lacroix-Triki, Julie Garrabey, Yannick Boursin, Marc Deloger, Yu Fu, Frédéric Commo, Véronique Scott, Ludovic Lacroix, Maria Vittoria Dieci, Maud Kamal, Véronique Diéras, Anthony Gonçalves, Jean-Marc Ferrerro, Gilles Romieu, Laurence Vanlemmens, Marie-Ange Mouret Reynier, Jean-Christophe Théry, Fanny Le Du, Séverine Guiu, Florence Dalenc, Gilles Clapisson, Hervé Bonnefoi, Marta Jimenez, Christophe Le Tourneau, Fabrice André
BACKGROUND: Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this disease. This study aims to decipher mutational profiles of mBC using next-generation sequencing. METHODS AND FINDINGS: Whole-exome sequencing was performed on 216 tumor-blood pairs from mBC patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA, or Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trials...
December 2016: PLoS Medicine
https://www.readbyqxmd.com/read/28008379/a-phase-2-trial-exploring-the-clinical-and-correlative-effects-of-combining-doxycycline-with-bone-targeted-therapy-in-patients-with-metastatic-breast-cancer
#12
C L Addison, D Simos, Z Wang, G Pond, S Smith, S Robertson, S Mazzarello, G Singh, L Vandermeer, R Fernandes, A Iyengar, S Verma, M Clemons
BACKGROUND: Bone-targeting agents (BTAs), such as bisphosphonates and denosumab, have demonstrated no discernable effects on tumour response or disease free/overall survival in patients with bone metastases from breast cancer. Doxycycline is both osteotropic and has anti-cancer effects. When combined with zoledronate in animal models, doxycycline showed significantly increased inhibition of tumour burden and increased bone formation. We evaluated the effects of adding doxycycline to ongoing anti-cancer therapy in patients with metastatic breast cancer...
November 2016: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28002240/longitudinal-computed-tomography-monitoring-of-pelvic-bones-in-patients-with-breast-cancer-using-automated-bone-subtraction-software
#13
Marius Horger, Wolfgang Maximilian Thaiss, Benjamin Wiesinger, Hendrik Ditt, Jan Fritz, Konstantin Nikolaou, Christopher Kloth
OBJECTIVE: The aim of this study was to optimize computed tomography (CT) surveillance of skeletal metastases in patients with breast cancer through the use of osseous subtraction maps between baseline and follow-up examinations created by a novel software algorithm. The new postprocessing algorithm segments the original bone followed by image intensity-based rigid alignment creating gray-shaded maps that highlight focal or diffuse loss or increase in bone attenuation. MATERIALS AND METHODS: Institutional review board was obtained for this retrospective data evaluation...
December 20, 2016: Investigative Radiology
https://www.readbyqxmd.com/read/27988895/radiopharmaceuticals-for-metastatic-bone-pain-palliation-available-options-in-the-clinical-domain-and-their-comparisons
#14
REVIEW
Tapas Das, Sharmila Banerjee
Bone pain arising due to skeletal metastases is one of the common complications experienced by the majority of patients suffering from prostate, breast and lung cancer at the advanced stage of the disease. These patients are subjected to palliative care in order to improve the quality of their remaining life. With the gradually increasing number of cancer cases, palliation of metastatic bone pain is gaining importance. Bone-seeking radiopharmaceuticals play a pivotal role in the management of cancer pain, particularly in patients with multiple metastases, as these agents are proven to be effective in controlling the bone pain with minimum side effects...
December 17, 2016: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/27982029/galnt14-promotes-lung-specific-breast-cancer-metastasis-by-modulating-self-renewal-and-interaction-with-the-lung-microenvironment
#15
Ki-Hoon Song, Mi So Park, Tulip S Nandu, Shrikanth Gadad, Sang-Cheol Kim, Mi-Young Kim
Some polypeptide N-acetyl-galactosaminyltransferases (GALNTs) are associated with cancer, but their function in organ-specific metastasis remains unclear. Here, we report that GALNT14 promotes breast cancer metastasis to the lung by enhancing the initiation of metastatic colonies as well as their subsequent growth into overt metastases. Our results suggest that GALNT14 augments the self-renewal properties of breast cancer cells (BCCs). Furthermore, GALNT14 overcomes the inhibitory effect of lung-derived bone morphogenetic proteins (BMPs) on self-renewal and therefore facilitates metastasis initiation within the lung microenvironment...
December 16, 2016: Nature Communications
https://www.readbyqxmd.com/read/27975154/prognostic-impact-of-metastatic-pattern-in-stage-iv-breast-cancer-at-initial-diagnosis
#16
Bernardo Amadeo Leone, Carlos Teodoro Vallejo, Alberto Omar Romero, Mario Raúl Machiavelli, Juan Eduardo Pérez, Julieta Leone, José Pablo Leone
PURPOSE: To analyze the prognostic influence of metastatic pattern (MP) compared with other biologic and clinical factors in stage IV breast cancer at initial diagnosis (BCID) and evaluate factors associated with specific sites of metastases (SSM). METHODS: We evaluated women with stage IV BCID with known metastatic sites, reported to the Surveillance, Epidemiology and End Results program from 2010 to 2013. MP was categorized as bone-only, visceral, bone and visceral (BV), and other...
December 14, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27959340/e-selectin-targeting-pegylated-thioaptamer-prevents-breast-cancer-metastases
#17
Yoshihiro Morita, Mohamed Kamal, Shin-Ae Kang, Roy Zhang, Ganesh Lr Lokesh, Varatharasa Thiviyanathan, Nafis Hasan, Sukyung Woo, Daniel Zhao, Macall Leslie, Stephen Suh, Wajeeha Razaq, Hallgeir Rui, David G Gorenstein, David E Volk, Takemi Tanaka
E-selectin is an adhesion molecule expressed on the luminal surface of inflamed blood vessels that mediates hematogenous metastasis by assisting shear-resistant adhesion of circulating tumor cells to the vessel surface under dynamic blood flow. Previously, we developed an E-selectin antagonistic thioaptamer (ESTA) for the prevention of hematogenous metastasis through the blockade of CD44(high) breast cancer cells (BCa) adhesion to E-selectin-expressing premetastatic endothelial niche. The current study focuses on developing a PEGylated E-selectin targeting thioaptamer with improved pharmaceutical properties...
December 13, 2016: Molecular Therapy. Nucleic Acids
https://www.readbyqxmd.com/read/27931250/tracing-the-origin-of-disseminated-tumor-cells-in-breast-cancer-using-single-cell-sequencing
#18
Jonas Demeulemeester, Parveen Kumar, Elen K Møller, Silje Nord, David C Wedge, April Peterson, Randi R Mathiesen, Renathe Fjelldal, Masoud Zamani Esteki, Koen Theunis, Elia Fernandez Gallardo, A Jason Grundstad, Elin Borgen, Lars O Baumbusch, Anne-Lise Børresen-Dale, Kevin P White, Vessela N Kristensen, Peter Van Loo, Thierry Voet, Bjørn Naume
BACKGROUND: Single-cell micro-metastases of solid tumors often occur in the bone marrow. These disseminated tumor cells (DTCs) may resist therapy and lay dormant or progress to cause overt bone and visceral metastases. The molecular nature of DTCs remains elusive, as well as when and from where in the tumor they originate. Here, we apply single-cell sequencing to identify and trace the origin of DTCs in breast cancer. RESULTS: We sequence the genomes of 63 single cells isolated from six non-metastatic breast cancer patients...
December 9, 2016: Genome Biology
https://www.readbyqxmd.com/read/27925188/a-human-3d-in-vitro-model-to-assess-the-relationship-between-osteoporosis-and-dissemination-to-bone-of-breast-cancer-tumour-cells
#19
F Salamanna, V Borsari, S Brogini, P Torricelli, S Cepollaro, M Cadossi, M Fini
Despite consistent improvements in diagnostic and therapeutic strategies for breast cancer, up to 40% of patients will develop bone metastases. To reduce the morbidity and complications related with bone metastases, it is imperative to reduce their etiological factors. Osteoporosis, being characterized by a sudden estrogen deficiency, may provide a favorable condition for bone metastasis. This work, using a humanized 3D in vitro model, aims at evaluating the relationship between osteoporosis and breast cancer-derived bone metastases...
December 7, 2016: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/27919267/targeted-drug-delivery-of-near-ir-fluorescent-doxorubicin-conjugated-poly-ethylene-glycol-bisphosphonate-nanoparticles-for-diagnosis-and-therapy-of-primary-and-metastatic-bone-cancer-in-a-mouse-model
#20
S Rudnick-Glick, E Corem-Salkmon, I Grinberg, S Margel
BACKGROUND: Most primary and metastatic bone tumors demonstrate increased osteoclast activity and bone resorption. Current treatment is based on a combination of surgery, radiotherapy and chemotherapy. Severe side effects are associated with chemotherapy due to use of high dosage and nonspecific uptake. Bisphosphonates have a strong affinity to Ca(2+) ions and are widely used in the treatment of bone disorders. RESULTS: We have engineered a unique biodegradable bisphosphonate nanoparticle (NPs) bearing two functional surface groups: (1) primary amine groups for covalent attachment of a dye/drug (e...
December 5, 2016: Journal of Nanobiotechnology
keyword
keyword
61124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"